Initial PrEP product choice: results from the HPTN 084 open-label extension

被引：0

作者：

Delany-Moretlwe, S. ^{[1
]}

Hanscom, B. ^{[2
]}

Angira, F. ^{[3
]}

Dadabhai, S. ^{[4
]}

Gadama, D. ^{[5
]}

Mirembe, B. ^{[6
]}

Bhondai, M.

Innes, S. ^{[8
]}

Kalonji, D. ^{[9
]}

Makhema, J. ^{[10
]}

Mandima, P. ^{[7
]}

Marais, A. ^{[11
]}

Mpendo, J. ^{[12
]}

Mukwekwerere, P. ^{[7
]}

Mgodi, N.

Naidoo, V. ^{[13
]}

Ntege, P. Nahirya ^{[14
]}

Nuwagaba-Biribonwoha, H. ^{[15
]}

Roos, E. ^{[1
]}

Singh, N. ^{[16
]}

Siziba, B. ^{[7
]}

Spooner, E.

Farrior, J. ^{[17
]}

Rose, S. ^{[17
]}

Piwowar-Manning, E. ^{[18
]}

Burton, M. ^{[19
]}

Soto-Torres, L. ^{[20
]}

Rooney, J. ^{[21
]}

Rinehart, A. ^{[22
]}

Cohen, M.

Hosseinipour, M. ^{[23
,24
]}

机构：

[1] Univ Witwatersrand, Wits RHI, Johannesburg, South Africa

[2] Fred Hutchinson Canc Res Inst, Stat Ctr HIV AIDS Res Prevent, Seattle, WA USA

[3] KEMRI, Kisumu, Kenya

[4] Coll Med Blanytre, Blantyre, Malawi

[5] UNC Project Malawi, Lilongwe, Malawi

[6] Johns Hopkins Univ Res Collaborat, Makerere Univ, Kampala, Uganda

[7] Univ Zimbabwe, Clin Trials Res Ctr, Harare, Zimbabwe

[8] Desmond Tutu Hlth Fdn, Cape Town, South Africa

[9] South African Med Res Council, HIV & Other Infect Dis Res Unit, Durban, South Africa

[10] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana

[11] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto, South Africa

[12] UVRI IAVI, Entebbe, Uganda

[13] Univ Stellenbosch, Desmond Tutu TB Ctr, Stellenbosch, South Africa

[14] Baylor Coll Med, Childrens Fdn Uganda, Kampala, Uganda

[15] Columbia Univ, Mailman Sch Publ Hlth, Eswatini Prevent Ctr, Mbabane, South Africa

[16] South African Med Res Council, Durban, South Africa

[17] FHI360, Durham, NC USA

[18] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[19] Fred Hutchinson Canc Res Inst, Seattle, WA USA

[20] NIAID, Rockville, MD USA

[21] Gilead Sci, Foster City, CA USA

[22] ViiV Healthcare, Durham, NC USA

[23] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[24] UNC Project Malawi, Lilongwe, Malawi

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2023年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

OALBX0203

引用

页数：2

共 50 条

[31] Safety and Tolerability of the Rivastigmine Patch Results of a 28-week Open-label Extension
Grossberg, George
Sadotvsky, Carl
Foerstl, Haas
Froelich, Lutz
Nagel, Jennifer
Tekin, Sibel
Zechner, Stefanie
Ros, Jacqueline
Orgogozo, Jean-Marc
[J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2009, 23 (02) : 158 - 164
[32] Long-term efficacy and safery of switching from Ustekinumab to Risankizuman: results from the open-label extension LIMMitless
Strober, Bruce
Eyerich, Killian
Hong, H. Chih-Ho
Zeng, Jiewei
Valdecantos, Wendell C.
Valdes, Joaquin
Bachelez, Herve
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 19 - 19
[33] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Cohen, Stanley
Pablos, Jose L.
Zhang, Nan
Rizzo, Warren
Muller, Gerhard
Padmanaban, Devi
Kivitz, Alan
Matsumoto, Alan K.
Kaur, Primal
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[34] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION study
Ashina, M.
Roos, C.
Ayer, D. W.
Ruff, D.
Krege, J. H.
Li, L. Q.
Komori, M.
[J]. HEADACHE, 2022, 62 : 113 - 114
[35] ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
Cohen, S.
Pablos, J. L.
Wang, H.
Mueller, G. A.
Kivitz, A.
Matsumoto, A.
Krishnan, E.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 834 - 835
[36] Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
Frishberg, Yaacov
Groothoff, Jaap W.
Hulton, Sally-Anne
Harambat, Jerome
Hogan, Julien
Anne-Laure, Sellier-Leclerc
Hayes, Wesley
Coenen, Martin
Willey, Richard
Gansner, John
Magen, Daniella
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
[37] The use of hyaluronic acid in the treatment of moderate to severe nasolabial folds: Results from an open-label extension trial
Narins, Rhoda
Maas, Corey
Jones, Derek
Monheit, Gary
Coleman, William, III
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB62 - AB62
[38] PASADENA 1-year Open-label Extension
Pagano, G.
Reyes, A.
Monnet, A.
Martinec, M.
Shariati, N.
Simuni, T.
Marek, K.
Postuma, R.
Pavese, N.
Stocchi, F.
Taylor, K.
Svoboda, H.
Fontoura, P.
Kerchner, G.
Doody, R.
Bonni, A.
Nikolcheva, T.
[J]. MOVEMENT DISORDERS, 2023, 38 : S44 - S44
[39] Open-label extension studies: Interpretation and statistical issues
Weatherall M.
Burgess C.
Taylor W.
[J]. International Journal of Pharmaceutical Medicine, 2007, 21 (2) : 115 - 120
[40] Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension
Nowak, Richard J.
Breiner, Ari
Bril, Vera
Allen, Jeffrey A.
Khan, Shaida
Levine, Todd
Jacobs, Daniel H.
Sahagian, Gregory
Siddiqi, Zaeem A.
Xu, Jing
Macias, William L.
Benatar, Michael
[J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (01): : 194 - 206

← 1 2 3 4 5 →